Three new agents for immunotherapy trials: azimexon, bestatin, and tuftsin.
D000276:Adjuvants, Immunologic / Q000627:therapeutic use*; D000818:Animals; D001388:Aziridines / Q000627:therapeutic use*; D001389:Azirines / Q000627:therapeutic use*; D003602:Cytotoxicity, Immunologic / Q000187:drug effects; D004353:Drug Evaluation, Preclinical; D007128:Immunoglobulin Fragments / Q000627:therapeutic use*; D007167:Immunotherapy; D007930:Leucine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D051379:Mice; D009374:Neoplasms, Experimental / Q000276:immunology / Q000628:therapy*; D013601:T-Lymphocytes / Q000276:immunology; D014405:Tuftsin / Q000627:therapeutic use*
D000276:Adjuvants, Immunologic; D001388:Aziridines; D001389:Azirines; D007128:Immunoglobulin Fragments; C016866:azimexon; D007930:Leucine; C012211:ubenimex; D014405:Tuftsin